Pregnancy related studies have centered on human studies supporting basic science collaborations in the area of angiogenic factors and preeclampsia. In dialysis, we have conducted studies examining the effect of vitamin D in the survival of chronic hemodialysis patients.

Dr. Thadhani began training at Massachusetts General Hospital and Harvard Medical School (HMS) in 1991, and has been the Chief of Nephrology at Mass General since 2013 - 2017, Professor of Medicine HMS and Executive Director of the Clinical Trials Office Mass General Brigham. He is a clinical and translational investigator and his research laboratory (established in 1999) has focused on understanding and treating disorders of pregnancy and understanding vitamin D metabolism with the priority being to positively impact clinical practice and improve patient outcomes. Dr. Thadhani and his collaborators have developed novel diagnostic tests for preeclampsia, and are now arduously working on therapies to safely prolong pregnancy in women with very severe preterm preeclampsia. He is actively performing first-in-human randomized trials based on extensive pilot studies (Circulation 2011 and the Journal of the American Society of Nephrology 2015). His pregnancy studies center on human research supporting recent findings emerging from basic science collaborations in the area of angiogenic factors and preeclampsia. He has performed pilot and proof-of-concept studies, retrospective and prospective (>10,000 women, > 30,000 blood samples) studies, and planned and performed interventional trials. A diagnostic test his team developed is currently in the clinic in Europe. With regard to vitamin D, his team has performed several hypothesis-generating observational studies suggesting that therapy with activated vitamin D sterols is associated with improved survival among patients with renal failure. These series of observational studies have included thousands of dialysis patients throughout the U.S. His studies have been confirmed by over 25 independent investigators world-wide. Clinical practices (academic and non-academic) have implemented practice patterns aligned with this work, and national and international practice guidelines have highlighted these studies. Acknowledging the observational nature of this work, however, he pursued animal models examining the cardiac effects of vitamin D with basic science collaborators. His series of human and animal experimental studies led to an investigator initiated (Thadhani, PI) multicenter multinational (> 60 centers world-wide) clinical trial in patients with kidney disease.